Abstract
Recent studies demonstrate that the peptides in the serum of cancer patients that are generated (ex vivo) as a result of tumor protease activity can be used for the detection and classification of cancer. In this paper, we propose the first formal approach to modeling exopeptidase activity from liquid chromatography–mass spectrometry (LC-MS) samples. We design a statistical model of peptidome degradation and a Metropolis-Hastings algorithm for Bayesian inference of model parameters. The model is successfully validated on a real LC-MS dataset. Our findings support the hypotheses about disease-specific exopeptidase activity, which can lead to new diagnostic approach in clinical proteomics.
Keywords
Get full access to this article
View all access options for this article.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
